Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Radiopharmaceuticals: A New Vista for Diagnosis and Treatment of Thyroid Cancer

Author(s): Siddhi Vernekar, Roja Rani Budha and Rajasekhar Reddy Alavala*

Volume 17, Issue 2, 2024

Published on: 11 January, 2024

Page: [148 - 162] Pages: 15

DOI: 10.2174/0118744710277275231112081003

Price: $65

Abstract

Radiopharmaceuticals are in the diagnosis and treatment of cancerous and noncancerous diseases, and a hope for optimistic effort in the field of nuclear medicine. They play a crucial role in clinical nuclear medicine by providing a tool to comprehend human disease and create efficient treatments. A detailed analysis is provided regarding the crux of molecular imaging including PET and SPECT overview for the detection of cancers. For a specified understanding of radiation therapy, topics include ranging from the selection of radionuclide to its development and manufacture, and dosage requirements to establishing the importance of I- 131 Radiotherapy in thyroid cancer. In this review, we also discussed the current state of the art of nuclear medicine in thyroid cancer, including the role of radioiodine (RAI) therapeutic scans in the diagnosis of differentiated thyroid cancer. In addition, we established a brief outlook into the current status of the research in thyroid cancer and discussed the future directions in this field.

« Previous Next »
Graphical Abstract

[1]
Weinberg Robert, A. How cancer arises. Sci. Am., 1996, 275(3), 62-70.
[http://dx.doi.org/10.1038/scientificamerican0996-62]
[2]
Yeong, C.H.; Cheng, M.; Ng, K.H. Therapeutic radionuclides in nuclear medicine: Current and future prospects. J. Zhejiang Univ. Sci. B, 2014, 15(10), 845-863.
[http://dx.doi.org/10.1631/jzus.B1400131] [PMID: 25294374]
[3]
World Health Organization. The international pharmacopoeia. radiopharmaceuticals: General monograph; , 2017. Available from: https://www.who.int/docs/default-source/medicines/norms-and-standards/current-projects/qas13-542rev2-general-chapter-radiopharmaceuticals.pdf?sfvrsn=516dbf81_2
[4]
Balogová, S. Nuclear endocrinology in the era of precision medicine. Q J. Nucl. Med. Mol. Imaging, 2022, 66(2), 83-85.
[5]
Kohli, K.; Chaudhary, H.; Rathee, P.; Rathee, S.; Kumar, V. Radiopharmaceutical: Revolutionary agents for diagnosis. Curr. Radiopharm., 2009, 2(2), 102-111.
[http://dx.doi.org/10.2174/1874471010902020102]
[6]
Radiopharmaceuticals. In: Nuclear Medicine, 4th ed; Ziessman, H.A.; O’Malley, J.P.; Thrall, J.H., Eds.; W.B. Saunders: Philadelphia, USA, 2014; pp. 1-15.
[http://dx.doi.org/10.1016/B978-0-323-08299-0.00001-8]
[7]
Marinović, M. Preparation of bifunctional ligands for radiometals conjugation to biomolecules, M.S thesis, University of Zagreb, Faculty of Chemical Engineering and Technology, Zagreb,, 2016.https://urn.nsk.hr/urn:nbn:hr:149:737280
[8]
Ogawa, K.; Ono, M.; Tian, M.; Ueda, M.; Higuchi, T. Development of radiolabeled compounds for molecular imaging and imaging-based therapy. ScientificWorldJournal, 2015, 2015, 1-2.
[http://dx.doi.org/10.1155/2015/365418] [PMID: 25884028]
[9]
Radiopharmaceuticals emerging as new cancer therapy. National cancer institute, 2020. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy (Accessed on October 26 2020).
[10]
Klain, M.; Zampella, E.; Nappi, C.; Nicolai, E.; Ambrosio, R.; Califaretti, E.; Lamartina, L.; Schlumberger, M.; Deandreis, D.; Salvatore, D.; Cuocolo, A. Advances in functional imaging of differentiated thyroid cancer. Cancers, 2021, 13(19), 4748.
[http://dx.doi.org/10.3390/cancers13194748] [PMID: 34638232]
[11]
World Nuclear Association (WNA). Radioisotopes in medicine., 2023. Available from: https://www.world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx (Accessed on February 2023).
[12]
Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; Schuff, K.G.; Sherman, S.I.; Sosa, J.A.; Steward, D.L.; Tuttle, R.M.; Wartofsky, L. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1), 1-133.
[http://dx.doi.org/10.1089/thy.2015.0020] [PMID: 26462967]
[13]
Luster, M.; Duntas, L.H.; Wartofsky, L. The thyroid and its diseases. A comprehensive guide for the clinician; , 2019. Available from: https://link.springer.com/book/10.1007/978-3-319-72102-6
[14]
Salih, S.; Alkatheeri, A.; Alomaim, W.; Elliyanti, A. Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. Molecules, 2022, 27(16), 5231.
[http://dx.doi.org/10.3390/molecules27165231] [PMID: 36014472]
[15]
Nguyen, Q.T.; Lee, E.J.; Huang, M.G.; Park, Y.I.; Khullar, A.; Plodkowski, R.A. Diagnosis and treatment of patients with thyroid cancer. Am. Health Drug Benefits, 2015, 8(1), 30-40.
[PMID: 25964831]
[16]
Pirola, I.; Brancato, D.; Negro, R.; Puxeddu, E.; Antonelli, A.; Delbarba, A.; Morelli, S.; Scorsone, A.; Cappelli, C. 15th international thyroid congress program and meeting abstracts. Thyroid, 2015, 25(S1)(Suppl. 1), p. P-1-A-337.
[http://dx.doi.org/10.1089/thy.2015.29004.abstracts] [PMID: 26465261]
[17]
Coura-Filho, G.B.; Torres Silva de Oliveira, M.; Morais de Campos, A.L. Differentiated thyroid cancer: Procedure’s techniques. In: Nuclear Medicine in Endocrine Disorders; Diagnosis and Therapy, 2022; pp. 147-153.
[http://dx.doi.org/10.1007/978-3-031-13224-7_16]
[18]
Alam, M.A.; Bharti, M.; Rao, G.S.N.K.; Sharma, P.K. A brief review of radioactive materials for therapeutic and diagnostic purposes. Curr. Radiopharm., 2023, 16(1), 23-37.
[http://dx.doi.org/10.2174/1874471016666221028110222] [PMID: 36306460]
[19]
Alsharef, S.; Alanazi, M.; Alharthi, F.; Qandil, D.; Qushawy, M. Review about radiopharmaceuticals: preparation, radioactivity, and applications. Intern. J. Applied Pharma., 2020, 12(3), 8-15.
[http://dx.doi.org/10.22159/ijap.2020v12i3.37150]
[20]
Giovanella, L.; Avram, A.; Clerc, J. Molecular imaging for thyrotoxicosis and thyroid nodules. J. Nucl. Med., 2021, 62(2), 20S-25S.
[http://dx.doi.org/10.2967/jnumed.120.246017] [PMID: 34230069]
[21]
Cox, AE; LeBeau, SO Diagnosis and treatment of differentiated thyroid carcinoma. Radiol. Clin., 2011, 49(3), 453-462.
[http://dx.doi.org/10.1016/j.rcl.2011.02.006]
[22]
Marinović, M. Preparation of bifunctional ligands for radiometals conjugation to biomolecules. Faculty of Chemical Engineering and Technology University of Zagreb, 2016.
[23]
Seminar. Thyroid carcinoma. Available from: https://c.coek.info/pdf-thyroid-carcinoma-.html (Accessed on Aug 2023).
[24]
Pisaneschi, F.; Viola, N.T. Development and validation of a PET/SPECT radiopharmaceutical in oncology. Mol. Imaging Biol., 2022, 24(1), 1-7.
[http://dx.doi.org/10.1007/s11307-021-01645-6] [PMID: 34542804]
[25]
Spirou, S.; Costa Lima, S.; Bouziotis, P.; Vranješ-Djurić, S.; Efthimiadou, E.; Laurenzana, A.; Barbosa, A.; Garcia-Alonso, I.; Jones, C; Jankovic, D.; Gobbo, O. Recommendations for in vitro and in vivo testing of magnetic nanoparticle hyperthermia combined with radiation therapy. Nanomaterials, 2018, 8(5), 306.
[http://dx.doi.org/10.3390/nano8050306] [PMID: 29734795]
[26]
Lau, J.; Rousseau, E.; Kwon, D.; Lin, K.S.; Bénard, F.; Chen, X. Insight into the development of PET radiopharmaceuticals for oncology. Cancers, 2020, 12(5), 1312.
[http://dx.doi.org/10.3390/cancers12051312] [PMID: 32455729]
[27]
Sgouros, G.; Bodei, L.; McDevitt, M.R.; Nedrow, J.R. Radiopharmaceutical therapy in cancer: Clinical advances and challenges. Nat. Rev. Drug Discov., 2020, 19(9), 589-608.
[http://dx.doi.org/10.1038/s41573-020-0073-9] [PMID: 32728208]
[28]
Society of Nuclear Medicine & Molecular Imaging. About Nuclear Medicine and Molecular Imaging., Available from: https://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=10450 (Accessed on 7 Aug 2023).
[29]
Peninsula Radiological Associates. Diagnostics tests., Available from: https://www.peninsularadiology.com/tag/hampton-roads-diagnosti-tests/ (Accessed on 7 Aug 2023).
[30]
Urbano, N.; Scimeca, M.; Bonfiglio, R.; Bonanno, E.; Schillaci, O. New advance in breast cancer pathology and imaging. Future Oncol., 2019, 15(23), 2707-2722.
[http://dx.doi.org/10.2217/fon-2019-0017] [PMID: 31339050]
[31]
Imam, S.K. Molecular nuclear imaging: The radiopharmaceuticals (review). Cancer Biother. Radiopharm., 2005, 20(2), 163-172.
[http://dx.doi.org/10.1089/cbr.2005.20.163] [PMID: 15869450]
[32]
Peerlinck, I.D.; Vassaux, G. Radioisotope delivery. Viral Ther. Cancer, 2008, 18, 327-340.
[http://dx.doi.org/10.1002/9780470985793.ch20]
[33]
Baum, R.P. Ed.; Therapeutic nuclear medicine; Springer: Berlin, Heidelberg, 2014.
[http://dx.doi.org/10.1007/978-3-540-36719-2]
[34]
Wells, R.G. Instrumentation in molecular imaging. J. Nucl. Cardiol., 2016, 23(6), 1343-1347.
[http://dx.doi.org/10.1007/s12350-016-0498-z] [PMID: 27072005]
[35]
World Nuclear Association. Radioisotopes in Medicine., Available from: https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx (Accessed on 7 Aug 2023).
[36]
Boccato Payolla, F.; Massabni, A.C.; Orvig, C. Radiopharmaceuticals for diagnosis in nuclear medicine: A short review. Eclét. Quím., 2019, 44(3), 11-19.
[http://dx.doi.org/10.26850/1678-4618eqj.v44.3.2019.p11-19]
[37]
World Health Organization. International conference on radiation safety: Improving radiation protection in practice. extended abstracts (Virtual Event). international atomic energy agency., 2021. Available from: https://www.iaea.org/sites/default/files/20/12/cn-279_book_of_abstracts.pdf
[38]
Crippa, F.; Alessi, A.; Gerali, A.; Bombardieri, E. FDG-PET in thyroid cancer. Tumori, 2003, 89(5), 540-543.
[http://dx.doi.org/10.1177/030089160308900517] [PMID: 14870781]
[39]
Badria, F.A. A Radiopharmaceuticals: On-Going research for better diagnosis, therapy, environmental, and pharmaceutical applications. In: Radiopharmaceuticals-Current Research for Better Diagnosis and Therapy; IntechOpen; , 2021.
[http://dx.doi.org/10.5772/intechopen.99204]
[40]
Rumyantsev, P.O.; Degtyarev, M.V.; Dzeytova, D.S.; Trukhin, A.A.; Slashchuk, K.Y.; Sheremeta, M.S.; Serzhenko, S.S.; Yasuchenia, V.S.; Sirota, Y.I. Thyroid scintigraphy in diagnosis of nodular and diffuse thyroid pathology. Clin. Exp. Thyroidol., 2020, 15(4), 138-147.
[http://dx.doi.org/10.14341/ket12240]
[41]
Bombardieri, E.; Seregni, E.; Evangelista, L.; Chiesa, C.; Chiti, A. Eds.; Clinical applications of nuclear medicine targeted therapy; Springer, 2018.
[http://dx.doi.org/10.1007/978-3-319-63067-0]
[42]
Cherk, M.H.; Kalff, V.; Yap, K.S.K.; Bailey, M.; Topliss, D.; Kelly, M.J. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131 I ablation therapy for differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.), 2008, 69(6), 957-962.
[http://dx.doi.org/10.1111/j.1365-2265.2008.03276.x] [PMID: 18419785]
[43]
Volterrani, D.; Erba, P.A.; Carrió, I.; Strauss, H.W.; Mariani, G. Nuclear medicine textbook: Methodology and clinical applications; Springer International Publishing, 2019. https://link.springer.com/book/10.1007/978-3-319-95564-3
[44]
Laulund, A.S.; Nybo, M.; Brix, T.H.; Abrahamsen, B.; Jørgensen, H.L.; Hegedüs, L. Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort. PLoS One, 2014, 9(10), e110437.
[http://dx.doi.org/10.1371/journal.pone.0110437] [PMID: 25340819]
[45]
Narayana, S.K.; Woods, D.R.; Boos, C.J. Management of amiodarone-related thyroid problems. Ther. Adv. Endocrinol. Metab., 2011, 2(3), 115-126.
[http://dx.doi.org/10.1177/2042018811398516] [PMID: 23148177]
[46]
Citterio, C.E.; Targovnik, H.M.; Arvan, P. The role of thyroglobulin in thyroid hormonogenesis. Nat. Rev. Endocrinol., 2019, 15(6), 323-338.
[http://dx.doi.org/10.1038/s41574-019-0184-8] [PMID: 30886364]
[47]
Khandelwal, D.; Tandon, N. Overt and subclinical hypothyroidism: Who to treat and how. Drugs, 2012, 72(1), 17-33.
[http://dx.doi.org/10.2165/11598070-000000000-00000] [PMID: 22191793]
[48]
Giovanella, L.; Avram, A.M.;; Ovčariček, P.P; Clerc, J. Thyroid functional and molecular imaging. Presse Med., 2022, 51(2), 104116.
[http://dx.doi.org/10.1016/j.lpm.2022.104116] [PMID: 35124101]
[49]
International atomic energy agency (IAEA) In: Operational guidance on hospital radiopharmacy: a safe and effective approach Vienna, 2008.
[50]
Ota, Y.; Avram, A.M. Nuclear medicine therapy of plummer adenoma. Nucl. Med. Mol. Imaging, 2022, 4, 27-30.
[http://dx.doi.org/10.1016/B978-0-12-822960-6.00176-9]
[51]
Kravets, I. Hyperthyroidism: Diagnosis and treatment. Am. Fam. Physician, 2016, 93(5), 363-370.
[PMID: 26926973]
[52]
Gillings, N.; Hjelstuen, O.; Ballinger, J.; Behe, M.; Decristoforo, C.; Elsinga, P.; Ferrari, V.; Peitl, P.K.; Koziorowski, J.; Laverman, P.; Mindt, T.L.; Neels, O.; Ocak, M.; Patt, M.; Todde, S. Guideline on current good radiopharmacy practice (cGRPP) for the smallscale preparation of radiopharmaceuticals. EJNMMI Radiopharm. Chem., 2021, 6(1), 8.
[http://dx.doi.org/10.1186/s41181-021-00123-2] [PMID: 33580358]
[53]
Coura-Filho, G.B.; de Oliveira, M.T.; de Campos, A.L. Nuclear medicine in endocrine disorders. In: Diagnosis and therapy; Springer Nature, 2022.
[54]
Sgouros, G. Radiopharmaceutical therapy. Health Phys., 2019, 116(2), 175-178.
[http://dx.doi.org/10.1097/HP.0000000000001000] [PMID: 30585960]
[55]
Giovanella, L.; Avram, A.M.; Iakovou, I.; Kwak, J.; Lawson, S.A.; Lulaj, E.; Luster, M.; Piccardo, A.; Schmidt, M.; Tulchinsky, M.; Verburg, F.A.; Wolin, E. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur. J. Nucl. Med. Mol. Imaging, 2019, 46(12), 2514-2525.
[http://dx.doi.org/10.1007/s00259-019-04472-8] [PMID: 31392371]
[56]
Fahey, F.H.; Goodkind, A.; Treves, S.T.; Grant, F.D. Nuclear medicine and radiation protection. J. Radiol. Nurs., 2016, 35(1), 5-11.
[http://dx.doi.org/10.1016/j.jradnu.2015.12.005]
[57]
Capala, J.; Graves, S.A.; Scott, A.; Sgouros, G.; James, S.S.; Zanzonico, P.; Zimmerman, B.E. Dosimetry for radiopharmaceutical therapy: Current practices and commercial resources. J. Nucl. Med., 2021, 62(3), 3S-11S.
[http://dx.doi.org/10.2967/jnumed.121.262749] [PMID: 34857621]
[58]
Croker, E.E.; McGrath, S.A.; Rowe, C.W. Thyroid disease: Using diagnostic tools effectively. Aust. J. Gen. Pract., 2021, 50(1-2), 16-21.
[http://dx.doi.org/10.31128/AJGP-10-20-5693] [PMID: 33543157]
[59]
RadiologyInfo.org. Thyroid cancer treatment: thyroid cancer overview., 2023. Available from: https://www.radiologyinfo.org/en/info/thyroid-cancer-treatment (Accessed 20 July 2023).
[60]
Urken, M.L.; Milas, M.; Randolph, G.W.; Tufano, R.; Bergman, D.; Bernet, V.; Brett, E.M.; Brierley, J.D.; Cobin, R.; Doherty, G.; Klopper, J.; Lee, S.; Machac, J.; Mechanick, J.I.; Orloff, L.A.; Ross, D.; Smallridge, R.C.; Terris, D.J.; Clain, J.B.; Tuttle, M. Management of recurrent and persistent metastatic lymph nodes in well‐differentiated thyroid cancer: A multifactorial decisionmaking guide for the thyroid cancer care collaborative. Head Neck, 2015, 37(4), 605-614.
[http://dx.doi.org/10.1002/hed.23615] [PMID: 24436291]
[61]
Parrilha, G.L.; dos Santos, R.G.; Beraldo, H. Applications of radiocomplexes with thiosemicarbazones and bis(thiosemicarbazones) in diagnostic and therapeutic nuclear medicine. Coord. Chem. Rev., 2022, 458, 214418.
[http://dx.doi.org/10.1016/j.ccr.2022.214418]
[62]
Sisson, J.C. Selection of the optimal scanning agent for thyroid cancer. Thyroid, 1997, 7(2), 295-302.
[http://dx.doi.org/10.1089/thy.1997.7.295] [PMID: 9133704]
[63]
Reynolds, JC.; Robbins, J. The changing role of radioiodine in the management of differentiated thyroid cancer., In Seminars in nuclear medicine, 1997, 27(2), 152-164.
[http://dx.doi.org/10.1016/S0001-2998(97)80045-1]
[64]
International Atomic Energy Agency (IAEC). Good practice for introducing radiopharmaceuticals for clinical use, IAEA-TECDOC-1782, IAEA, vienna; , 2015. Available from: https://www.iaea.org/publications/10829/good-practice-for-introducing-radiopharmaceuticals-for-clinical-use
[65]
Mettler, F.A., Jr; Guiberteau, M.J. Essentials of nuclear medicine imaging, 6th ed; , 2012.
[http://dx.doi.org/10.1016/C2009-0-61619-6]
[66]
Hedayati, M.; Shafaghati, N.; Hosseinimehr, S.J. Resveratrol mitigates genotoxicity induced by iodine-131 in primary human lymphocytes. Radiat. Environ. Biophys., 2013, 52(2), 287-291.
[http://dx.doi.org/10.1007/s00411-013-0461-1] [PMID: 23435954]
[67]
Schlumberger, M.; Garcia, C.; Hadoux, J.; Klain, M.; Lamartina, L. Functional imaging in thyroid cancer patients with metastases and therapeutic implications. Presse Med., 2022, 51(2), 104113.
[http://dx.doi.org/10.1016/j.lpm.2022.104113] [PMID: 35131318]
[68]
O’Brien, S.R.; Pryma, D.A. Introduction to radiopharmaceutical therapy. Pract. Radiat. Oncol., 2022, 12(4), 285-288.
[http://dx.doi.org/10.1016/j.prro.2022.04.006] [PMID: 35717041]
[69]
Hänscheid, H.; Lassmann, M. Will SPECT/CT cameras soon be able to display absorbed doses? Dosimetry from single-activity-concentration measurements. J. Nucl. Med., 2020, 61(7), 1028-1029.
[http://dx.doi.org/10.2967/jnumed.119.239970] [PMID: 31924721]
[70]
Amanda, E.; Kimberly, L.; Manu, G. Fundamentals of nursing pharmacology – 1st Canadian. In: Thyroid Basics: A&P Review; https://opentextbc.ca/nursingpharmacology/chapter/9-6-thyroid-medications/
[71]
Grupen, C. Introduction to radiation protection: practical knowledge for handling radioactive sources; Springer: Berlin, Heidelberg, 2010.
[http://dx.doi.org/10.1007/978-3-642-02586-0]
[72]
Leung, A.M.; Braverman, L.E. Iodine-induced thyroid dysfunction. Curr. Opin. Endocrinol. Diabetes Obes., 2012, 19(5), 414-419.
[http://dx.doi.org/10.1097/MED.0b013e3283565bb2] [PMID: 22820214]
[73]
Peng, C.C-H.; Pearce, E.N. An update on thyroid disorders in the postpartum period. J. Endocrinol. Invest., 2022, 45(8), 1497-1506.
[http://dx.doi.org/10.1007/s40618-022-01762-1] [PMID: 35181848]
[74]
Ritt, P. Recent developments in SPECT/CT. Semin. Nucl. Med., 2022, 52(3), 276-285.
[http://dx.doi.org/10.1053/j.semnuclmed.2022.01.004]
[75]
World Health Organisation. WHO Drug Information; International Nonproprietary Names for Pharmaceutical Substances, 2021.
[76]
Handbook On Chemicals And Hazardous Waste Management And Handling In India. Centre For Environmental Law, Education, Research and Advocacy National Law School Of India University, Ministry of Environment, Forest And Climate Change,; Government of India, 2019.
[77]
Nelson, B.J.B.; Andersson, J.D.; Wuest, F.; Spreckelmeyer, S. Good practices for 68Ga radiopharmaceutical production. EJNMMI Radiopharm. Chem., 2022, 7(1), 27.
[http://dx.doi.org/10.1186/s41181-022-00180-1] [PMID: 36271969]
[78]
Singh, I. Metallic radionuclides inside the development of diagnostic and healing radiopharmaceuticals. Nuclear Med. Rad. Ther., 2021, 12(11), 1-2.
[79]
Public Policy forum. Pathways to sustainable access to innovative medicines for canadians, Available from: https://ppforum.ca/publications/pathways-sustainable-access-innovative-medicines-canadians/ (Accessed on April 20 2018).
[80]
Wong, K.K.; Laird, A.M.; Moubayed, A.; Chondrogiannis, S.; Marzola, M.C.; Evangelista, L.; Gross, M.D.; Rubello, D. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals. Nucl. Med. Commun., 2012, 33(7), 679-688.
[http://dx.doi.org/10.1097/MNM.0b013e3283529bf7] [PMID: 22422100]
[81]
Paez, D.; Giammarile, F.; Orellana, P. Nuclear medicine: A global perspective. Clin. Transl. Imaging, 2020, 8(2), 51-53.
[http://dx.doi.org/10.1007/s40336-020-00359-z]

Rights & Permissions Print Cite
Article Metrics
2
© 2024 Bentham Science Publishers | Privacy Policy